FindTrial
Sign In

Correlation between BCG infusion outcomes and tumor microenvironment in non-muscle-invasive bladder cancer after TURBT surgery and the construction of a prediction model

Correlation between BCG infusion outcomes and tumor microenvironment in non-muscle-invasive bladder cancer after TURBT surgery and the construction of a prediction model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400085024
Enrollment
Unknown
Registered
2024-05-29
Start date
2024-05-29
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

BCG non-response group:None
BCG failure group:None
BCG response group:None

Sponsors

Lanzhou University Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Intermediate- and high-risk non-muscle-invasive bladder cancer;2. Patients who choose BCG perfusion therapy after TURBT;3. Patient age= 18 years old;4. Have complete and detailed clinical, pathological and follow-up data records;5. Patient informed and consenting to this study.

Exclusion criteria

Exclusion criteria: (1) Myometrial invasive, metastatic bladder cancer or other tumors; (2) switching to other perfusion drugs in the initial stage of treatment due to BCG intolerance, drug shortages, and other factors; (3) death due to other factors during the follow-up period; (4) Patients with severe liver and kidney function and bone marrow insufficiency; (5) Incomplete follow-up data due to patient loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Tumor immune cells;—

Secondary

MeasureTime frame
Tumor-associated fibroblasts;—

Countries

China

Contacts

Public ContactWang zhiping

Lanzhou University Second Hospital

erywzp@lzu.edu.cn+86 138 9313 1697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026